Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD137 agonistic monoclonal antibody ADG206

An Fc-enhanced immunoglobulin G1 (IgG1) monoclonal antibody directed against the costimulatory receptor CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9) covalently linked to a peptide mask, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD137 agonistic monoclonal antibody ADG206 is selectively activated in the tumor microenvironment (TME), and targets, binds to, and activates CD137 expressed on a variety of leukocyte subsets including activated T lymphocytes and natural killer (NK) cells. This enhances CD137-mediated signaling, induces cytokine production and promotes T-cell mediated anti-tumor immuneresponses. CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-4-1BB agonistic monoclonal antibody ADG206
anti-CD137 agonist monoclonal antibody ADG206
anti-CD137 monoclonal antibody ADG206
Code name:ADG 206
ADG-206
ADG206
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search